glp-1 gip dual agonist Pharmacogenomics of Tirzepatide: Genomic Insights into GIP/GLP-1 Response in Type 2 Diabetes and Atherosclerosis Free Comparison Chart: GLP-1 and
Description
2021 [cited 2026 Jan 9]
However, the reduction in HF hospitalisations with semaglutide did not reach statistical significance
Chiang PC, Hsieh CY, Sung SF
In 2025, Liquid I.V
Recommendations from the study include that more extensive multicenter studies or prospective clinical trials are needed to confirm findings and explore causality
[13] Insulin, for instance, requires multiple daily injections, which can be challenging for patients, [14] and while metformin is generally well-tolerated, its safety profile remains somewhat controversial, as it crosses the placenta
